Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 – Seasonal variation and association with outcome
The prevalence of irAEs in real-world patients is comparable to the observed risk in clinical trials. Patients experiencing irAEs demonstrate a lower risk of melanoma relapse. Further, gender, age and seasonal variation may impact the incidence of irAEs.
Authors
- Kasper Madsen (ORCID: https://orcid.org/0009-0006-7612-3906)
- Rikke B. Holmstroem
- Louise Mahncke Guldbrandt
- Marco Donia (ORCID: https://orcid.org/0000-0003-4966-9752)
- Eva Ellebæk (ORCID: https://orcid.org/0000-0001-6748-9232)
- Rebecca Jurlander
- Christina H. Bruvik Ruhlmann (ORCID: https://orcid.org/0000-0002-3728-273X)
- Charlotte Aaquist Haslund (ORCID: https://orcid.org/0009-0004-6571-2196)
- Inge Marie Svane (ORCID: https://orcid.org/0000-0002-9451-6037)
- Lars Bastholt (ORCID: https://orcid.org/0000-0001-5478-9826)
- Henrik Schmidt (ORCID: https://orcid.org/0000-0002-4063-3561)
Institutions
- Aalborg University Hospital (DK)
- Odense University Hospital (DK)
- Aarhus University Hospital (DK)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1016/j.ejca.2024.115053
- Citations
- 12
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.39
Funders
- Les Laboratories Pierre Fabre
- Sundhedsstyrelsen
- Novo Nordisk Fonden